Mazdak Momeni, MD
Gynecologic Oncology · Loma Linda, CANPI 1275865917
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,790 of the $21,186 with a category attached, or 74.5%. Merck accounts for 80.7% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $13,108, more than ten times the $118 reported in 2019.
Across 36 payments — averaging $588.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$17K
- AstraZeneca$3K
- GSK$172
- Verastem, Inc.$153
- Intuitive Surgical$134
- AbbVie$125
- plus $645 from 7 others
What the payments were for
- Consulting fees$2,49812%
- Speaking & faculty fees$15,79075%
- Travel & lodging$1,0195%
- Food & beverage$1,8159%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 13 | $17,093 |
| AstraZeneca | 8 | $2,864 |
| GSK | 2 | $172 |
| Verastem, Inc. | 1 | $153 |
| Intuitive Surgical | 2 | $134 |
| AbbVie | 1 | $125 |
| Dysis Medical, Inc. | 1 | $124 |
| Lilly USA, LLC | 1 | $124 |
| Tesaro, Inc. | 1 | $118 |
| Fennec Pharmaceuticals, Inc. | 1 | $96 |
| Myriad Genetic Laboratories, Inc. | 1 | $85 |
| Corcept Therapeutics | 3 | $82 |
| Monaghan Medical Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$12,476
- LYNPARZA$7,021
- AVMAPKI FAKZYNJA CO-PACK$153
- Elahere$125
- DYSIS Ultra 2.0$124
- DYSIS v3 Digital Coploscope$124
- DYSIS VIEW$124
- VERZENIO$124
- ZEJULA$118
- JEMPERLI$108
How this compares
$21,186 in reported general payments places this provider in the 80th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $3,373 |
| Megestrol Acetate | 26 | $1,038 |
| Letrozole | 16 | $333 |
| Prochlorperazine Maleate | 25 | $295 |
| Ondansetron Hcl | 41 | $220 |
| Dexamethasone | 29 | $218 |
| Ibuprofen | 12 | $93 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Loma Linda
- John ChanSan Francisco$2M
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
- Amer KaramStanford$168K
- Rebecca BrooksSacramento$133K
- Kenneth KimWest Hollywood$88K
- Oliver DorigoStanford$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.